B. Riley analyst Yuan Zhi initiated coverage of Ambrx Biopharma with a Buy rating and $26 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AMAM:
- Ambrx Appoints Jared Kelly as General Counsel
- Ambrx to Present at Multiple Upcoming Investor Meetings
- Ambrx Announces $75 Million Market Priced Registered Offering
- Ambrx Appoints Stephen Glover as Chairman of its Board of Directors
- Ambrx to Present at JMP Securities Life Sciences and RBC Capital Markets Global Healthcare Conferences